摘要
目的:研究Bcl-2、Ki-67在恶性淋巴瘤(Malignant lymphoma,ML)组织中的表达以及与自体造血干细胞移植(autologous 1hematopoietic stem cell transplantation,AHSCT)预后的相关关系。方法:1)采用免疫组织化学(immunohistochemistry,IHC)法检测33例行AHSCT治疗的患者组织切片中Ki-67,Bcl-2的表达。并探讨Ki-67,Bcl-2的表达与预后的相关性。 2)生存率统计采用Kaplan-Meier生存曲线,Log-rank检验,多因素分析采用Cox风险回归模型。结果:1)33例AHSCT治疗组,Bcl-2阳性表达组和阴性表达组移植后3年无病生存率分别为35.71%和88.89%(P<0.05);Ki-67阳性表达组和阴性表达组3年无病生存率分别为43.75%和85.71%(P<0.05),提示Bcl-2和Ki-67的表达与AHSCT的预后相关。2)Cox多因素分析显示,Ki-67和Bcl-2是影响ML患者AHSCT后无病生存的相关因素(P=0.043 7)。结论:Bcl-2、Ki-67蛋白阳性表达的ML患者,AHSCT后易复发,可作为移植后预后判断的指标之一。Ki-67和Bcl-2是影响ML患者AHSCT无病生存的独立相关因素。
Objective： To study the relationship of Bcl-2 and Ki-67 expression with the prognosis of malignant lymphoma （ML） patients after autologous hematopoietic stem cell transplantation （AHSCT）. Methods： Bcl-2 and Ki-67.protein expression was assessed with immunohistochemistry （IHC） using paraffin-embedded sections from 33 ML cases who received AHSCT. Survival analysis was performed with Kaplan-Meier method and log-rank test. We used Cox proportional hazards model to carry out multivariate analysis. Results： For ML patients after AHSCT, the 3-year disease free survival （DFS） was 35.71% in the Bcl-2-positive group and 88.89% in the Bcl-2-negative group, with a significant difference. The 3-year DFS was 43.75% in the Ki-67-positive group and 85.71% in the K[-67-negative group （P〈0.05）. Multivariate anatysis showed that the expression of Bcl-2 and Ki-67 were independent prognostic factors. Conclusion： The expression of Bcl-2 and Ki-67 was closely related to relapse in ML patients after AHSCT and can be used as a molecular marker to establish a prognosis for ML patients after AHSCT.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2009年第6期337-339,共3页
Chinese Journal of Clinical Oncology
关键词
恶性淋巴瘤
造血干细胞移植
预后
免疫组织化学
Malignant Lymphoma
Hematopoietic stem cell transplantation
Prognosis
Immunohistochemistry
